Evidence map›Paper›PMID 37166076›Full record

ArticleThe Journal of infectious diseases2023

Reduced Exercise Capacity, Chronotropic Incompetence, and Early Systemic Inflammation in Cardiopulmonary Phenotype Long Coronavirus Disease 2019.

Matthew S Durstenfeld, Michael J Peluso, Punita Kaveti, Christopher Hill, Danny Li, Erica Sander, Shreya Swaminathan, Victor M Arechiga, Scott Lu, Sarah A Goldberg and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pathophysiological Mechanisms in Long COVID: A Mixed Method Systematic Review.International journal of environmental research and public health · 2024
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 2 institutions in 1 country.

Matthew S DurstenfeldDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-7612-3352
Michael J PelusoDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Punita KavetiDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Christopher HillSchool of Medicine, University of California, San Francisco, San Francisco, California, USA.
Danny LiDivision of Cardiology, Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, California, USA.
Erica SanderDivision of Cardiology, UCSF Health, San Francisco, California, USA.
Shreya SwaminathanDivision of Cardiology, Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, California, USA.
Victor M ArechigaDivision of Cardiology, Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, California, USA.
Scott LuDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Sarah A GoldbergSchool of Medicine, University of California, San Francisco, San Francisco, California, USA.
Rebecca HohDivision of Cardiology, Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, California, USA.
Ahmed ChennaMonogram Biosciences, LabCorp, University of California, San Francisco, California, USA.
Brandon C YeeMonogram Biosciences, LabCorp, University of California, San Francisco, California, USA.
John W WinslowMonogram Biosciences, LabCorp, University of California, San Francisco, California, USA.
Christos J PetropoulosMonogram Biosciences, LabCorp, University of California, San Francisco, California, USA.
J Daniel KellyInstitute of Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Timothy J HenrichDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Yoo Jin LeeCardiac and Pulmonary Imaging, Department of Radiology, University of California, San Francisco, San Francisco, California, USA.
Mandar A ArasDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Carlin S LongDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Donald J GrandisDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Priscilla Y HsueDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USSan Francisco General Hospital · US

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDiseaseK24AI112393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y. · 2014 to 2024
$1.9M
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)K12HL143961 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y., HUANG, LAURENCE · 2018 to 2022
$1.8M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
NCATS NIH HHS UL1 TR001872NHLBI NIH HHS K12 HL143961NHLBI NIH HHS L30 HL159695NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS K24 AI112393NIAID NIH HHS L30 AI126521NIAID NIH HHS L30 AI147159NIAID NIH HHS P30 AI027763
6 · The paper itself

Abstract

backgroundMechanisms underlying persistent cardiopulmonary symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (postacute sequelae of coronavirus disease 2019 [COVID-19; PASC] or "long COVID") remain unclear. This study sought to elucidate mechanisms of cardiopulmonary symptoms and reduced exercise capacity.

methodsWe conducted cardiopulmonary exercise testing (CPET), cardiac magnetic resonance imaging (CMR) and ambulatory rhythm monitoring among adults >1 year after SARS-CoV-2 infection, compared those with and those without symptoms, and correlated findings with previously measured biomarkers.

resultsSixty participants (median age, 53 years; 42% female; 87% nonhospitalized; median 17.6 months after infection) were studied. At CPET, 18/37 (49%) with symptoms had reduced exercise capacity (<85% predicted), compared with 3/19 (16%) without symptoms (P = .02). The adjusted peak oxygen consumption (VO2) was 5.2 mL/kg/min lower (95% confidence interval, 2.1-8.3; P = .001) or 16.9% lower percent predicted (4.3%-29.6%; P = .02) among those with symptoms. Chronotropic incompetence was common. Inflammatory markers and antibody levels early in PASC were negatively correlated with peak VO2. Late-gadolinium enhancement on CMR and arrhythmias were absent.

conclusionsCardiopulmonary symptoms >1 year after COVID-19 were associated with reduced exercise capacity, which was associated with earlier inflammatory markers. Chronotropic incompetence may explain exercise intolerance among some with "long COVID."

Indexed as

COVID-19Exercise ToleranceContrast MediaFemaleGadoliniumHeart RateHumansInflammationMalePhenotypeSARS-CoV-2Contrast MediaGadoliniumcardiac magnetic resonance imagingcardiopulmonary exercise testingchronotropic incompetencepostacute sequelae of COVID-19SARS-CoV-2

Identifiers

PMID37166076
PMCPMC10686699
OpenAlexW4376133067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.